metformin has been researched along with losartan in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (10.71) | 29.6817 |
2010's | 20 (71.43) | 24.3611 |
2020's | 5 (17.86) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bundrick, JB; Litin, SC | 1 |
Balink, H; de Graaf, W; Grond, J; Hemmelder, MH | 1 |
Harrison, SA; Jones, FJ; Shaw, JC; Torres, DM; Ward, JA; Williams, CD | 1 |
Pirola, CJ; Sookoian, S | 1 |
Clouatre, DL; Preuss, HG; Rao, SN | 1 |
Chalasani, N; Corey, KE | 1 |
Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T | 1 |
Arafat, T; Idkaidek, N | 1 |
Barreto-Torres, G; Hernández, JS; Javadov, S; Khuchua, Z; Kuznetsov, AV | 1 |
Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
Ahn, HY; Ha, TS; Park, HY; Seong, SB | 1 |
Jang, HB; Jeon, JY; Kim, MG; Kim, SY; Lim, CH; Moon, SJ | 1 |
Ahmed, M; Ali, M; Ayatollahi, SA; Esfahanizadeh, M; Haider, SM; Hasan, A; Khan, KM; Kobarfard, F | 1 |
Glick, A; Johnson, C; Sista, V | 1 |
Aung, TKK; Chua, MWJ; Chuah, TY | 1 |
da Silva, SVS; de Carvalho, WC; de Freitas Santos Júnior, A; de Jesus, ACL; de Sousa, TL; Dos Santos, LC; Korn, MDGA; Santos, DCMB; Souza, LA | 1 |
Ahante, E; Anachuna, KK; Asiwe, JN; Ben-Azu, B; Edje, KE; Eduviere, AT; Moke, EG; Oghoghovwe, IJ; Omogbai, EKI; Omogbiya, AI; Osagie-Eweka, SDE; Uchendu, AP; Umukoro, EK | 1 |
Tchernev, G | 1 |
1 review(s) available for metformin and losartan
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for metformin and losartan
Article | Year |
---|---|
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Losartan; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2011 |
Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers.
Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Healthy Volunteers; Humans; Linagliptin; Losartan; Male; Metformin; Middle Aged; Morus; Plant Extracts; Pueraria; Young Adult | 2017 |
25 other study(ies) available for metformin and losartan
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Clinical pearls in general internal medicine.
Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Infective Agents, Urinary; Antihypertensive Agents; Calcium Channel Blockers; Creatinine; Diagnosis, Differential; Female; Fenofibrate; Gout; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Internal Medicine; Losartan; Male; Metformin; Nifedipine; Potassium; Sulfonamides; Tamsulosin; Trimethoprim; Ureteral Calculi; Vitamin B 12 Deficiency | 2011 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Chester Disease; Gated Blood-Pool Imaging; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Hypolipidemic Agents; Imidazoles; Knee Joint; Losartan; Male; Metformin; Positron-Emission Tomography; Prostatic Neoplasms; Simvastatin | 2011 |
Targeting the renin-angiotensin system: potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis.
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Thiazolidinediones | 2011 |
Bitter melon extracts in diabetic and normal rats favorably influence blood glucose and blood pressure regulation.
Topics: Animals; Blood Glucose; Blood Pressure; Cucurbitaceae; Diabetes Mellitus, Experimental; Fruit; Glucose Tolerance Test; Hypoglycemic Agents; Losartan; Male; Metformin; NG-Nitroarginine Methyl Ester; Nitric Oxide; Plant Extracts; Rats; Rats, Sprague-Dawley; Rats, Wistar; Renin-Angiotensin System | 2011 |
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones | 2011 |
Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diet, High-Fat; Disease Models, Animal; Hypertension; Kidney; Losartan; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Phosphorylation; Sodium; Sodium, Dietary | 2012 |
Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
Topics: Acetates; Anthraquinones; Azithromycin; Benzhydryl Compounds; Cinacalcet; Cloxacillin; Cresols; Cyclopropanes; Female; Fluorobenzenes; Humans; Hydrochlorothiazide; Losartan; Male; Metformin; Naphthalenes; Phenylpropanolamine; Piroxicam; Pyrazines; Pyrimidines; Quinolines; Rosuvastatin Calcium; Saliva; Sitagliptin Phosphate; Sulfides; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Triazoles | 2012 |
Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Gene Expression Regulation; Losartan; Metformin; Mitochondria; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Rats; Receptor, Angiotensin, Type 1; Signal Transduction; Sirtuin 1; Tumor Suppressor Protein p53 | 2014 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
Angiotensin II Modulates p130Cas of Podocytes by the Suppression of AMP-Activated Protein Kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cell Line; Cell Nucleus; Crk-Associated Substrate Protein; Cytoplasm; Focal Adhesion Kinase 1; Losartan; Metformin; Mice; Microscopy, Confocal; Podocytes; Protein Kinase Inhibitors; Ribonucleotides; Signal Transduction | 2016 |
Short Communication - Synthesis of drug metal complexes and their influence on human platelet aggregation.
Topics: Coordination Complexes; Drug Evaluation, Preclinical; Fluconazole; Humans; Isoniazid; Losartan; Metformin; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazinamide | 2018 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes Mellitus, Type 2; Edema; Glucocorticoids; Hand; Humans; Hypertension; Hypoglycemic Agents; Losartan; Male; Metformin; Prednisolone; Rotator Cuff Injuries; Syndrome; Synovitis | 2021 |
Effect of losartan potassium, metformin hydrochloride, and simvastatin on in vitro bioaccessibility of Cu, Fe, Mn, and Zn in oat flour from Brazil.
Topics: Avena; Brazil; Flour; Humans; Losartan; Metformin; Micronutrients; Simvastatin; Zinc | 2022 |
Co-administration of metformin and/or glibenclamide with losartan reverse N
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Esters; Glyburide; Hypertension; Hypoglycemic Agents; Losartan; Metformin; NG-Nitroarginine Methyl Ester; Rats; Streptozocin; Water | 2023 |
NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAR
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Tricyclic; Bisoprolol; Calcium Channel Blockers; Enalapril; Humans; Incidence; Losartan; Metformin; Paroxetine; Perindopril; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Skin Neoplasms; Valsartan; Venlafaxine Hydrochloride | 2023 |